CivicaScript
CivicaScript is a nonprofit pharmaceutical company, founded in 2020 as a subsidiary of Civica, Inc., that develops and distributes low-cost generic medicines and biosimilars to U.S. payers, PBMs, and pharmacies through its MaxRP transparent pricing model. It is governed by Blue Cross Blue Shield plans, Elevance Health, and PBM members covering tens of millions of lives.
- Company typePrivate
- Founded2020
- HeadquartersLehi, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What CivicaScript does
CivicaScript is a nonprofit pharmaceutical company, organized as an LLC and operating as the outpatient-medicines unit of parent nonprofit Civica, Inc. Founded in 2020 and headquartered in Lehi, Utah, with a manufacturing/operations facility in Petersburg, Virginia, the company develops, manufactures, and distributes low-cost generic medicines and biosimilars targeting high-priced outpatient drugs where generic pricing has failed patients. Its portfolio spans specialty generics (abiraterone/Abirtega for prostate cancer, capecitabine for colorectal/breast/gastric/esophageal/pancreatic cancer, dalfampridine for multiple sclerosis, dimethyl fumarate for chronic inflammatory conditions, droxidopa for orthostatic hypotension) and biosimilars (insulin glargine-yfgn interchangeable with Lantus, and ustekinumab-aauz for immunology indications). Products are sourced through manufacturer partnerships including Biocon Biologics (insulin) and Fresenius Kabi (ustekinumab).
The company sells products to pharmacies at wholesale prices with a publicly disclosed Maximum Retail Price (MaxRP) cap enforced via its Unilateral Pricing Policy and QR-code-enabled package verification, eliminating conventional markup opacity. CivicaScript is funded and governed by its members: 18 founding independent Blue Cross and Blue Shield plans, the Blue Cross Blue Shield Association, Elevance Health/CarelonRx (covering more than 47 million lives), and PBMs including Navitus Health Solutions, Affirmed Rx, and SelectHealth/Scripius. Distribution flows through these payer and PBM channels to pharmacies and, in California, through the state CalRx program for insulin. Per NEJM Catalyst (Vol. 6 No. 6, June 2025), switching to CivicaScript abiraterone yielded 64% cost savings for patients and 92% for payers; the company reported $16 million in savings delivered in 2025 and nearly $44 million cumulatively since its 2022 product launch.
CivicaScript firmographics
Firmographics- Name
- CivicaScript
- Legal name
- CivicaScript, LLC
- Website
- https://civicascript.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- CivicaScript is a nonprofit pharmaceutical company, founded in 2020 as a subsidiary of Civica, Inc., that develops and distributes low-cost generic medicines and biosimilars to U.S. payers, PBMs, and pharmacies through its MaxRP transparent pricing model. It is governed by Blue Cross Blue Shield plans, Elevance Health, and PBM members covering tens of millions of lives.
- Ownership category
- akta.pro rank
CivicaScript industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Civic and Social Organizations (81341)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- 340B Program Administration & Contract Pharmacy Services (HLAFALAL)
Keywords
Where CivicaScript is headquartered
LocationHeadquarters
- HQ city
- Lehi
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CivicaScript business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Medicine Sales: CivicaScript manufactures low-cost generic medicines and works with payers, PBMs and pharmacies across the country to pass along cost savings to patients. As a nonprofit, revenue is reinvested to support the mission of providing affordable essential generic medicines.
- Biosimilar Distribution: CivicaScript distributes biosimilars including insulin glargine-yfgn and ustekinumab-aauz. Products are sold to pharmacies at wholesale prices with maximum recommended retail prices to consumers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Abirtega (abiraterone), 250 mg: 120 tablets - $141 |
| Unit Pricing | Pay-as-you-go | Capecitabine, 150 mg: 60 tablets - $38 |
| Unit Pricing | Pay-as-you-go | Capecitabine, 500 mg: 120 tablets - $84 |
| Unit Pricing | Pay-as-you-go | Civica insulin glargine-ygfn, box of 5 prefilled pens - $55 |
| Unit Pricing | Pay-as-you-go | Dalfampridine, 10 mg: 60 extended-release tablets - $37 |
| Unit Pricing | Pay-as-you-go | Dimethyl fumarate, 120 mg: 14 capsules - $46 |
| Unit Pricing | Pay-as-you-go | Dimethyl fumarate, 240 mg: 60 capsules - $68 |
| Unit Pricing | Pay-as-you-go | Droxidopa, 100 mg: 90 capsules - $65 |
| Unit Pricing | Pay-as-you-go | Droxidopa, 200 mg: 90 capsules - $109 |
| Unit Pricing | Pay-as-you-go | Droxidopa, 300 mg: 90 capsules - $153 |
| Unit Pricing | Pay-as-you-go | Ustekinumab-aauz, 45 mg - $625 |
| Unit Pricing | Pay-as-you-go | Ustekinumab-aauz, 90 mg - $1,035 |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
CivicaScript product offering
Product offeringCore offering
CivicaScript is a nonprofit pharmaceutical company that manufactures and distributes low-cost essential generic medicines and biosimilars through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The company employs a Maximum Retail Price (MaxRP) pricing policy with QR-code-based verification to ensure price transparency throughout the supply chain, passing savings to patients and health plan members.
Product overview
CivicaScript is a nonprofit pharmaceutical company operating as the Civica, Inc. operating unit for outpatient medications, focused on making essential generic medicines and biosimilars affordable and available to everyone. The company manufactures and distributes low-cost generic medicines through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The portfolio includes specialty generics (Abirtega/abiraterone, capecitabine, dalfampridine, dimethyl fumarate, droxidopa) and biosimilars (insulin glargine-yfgn, ustekinumab-aauz). All products feature the MaxRP pricing policy enabling price transparency through QR codes. The business model emphasizes transparency and collaboration throughout the supply chain from manufacturing through dispensing.
Differentiator
Problem solved
Functional benefit
Brands
- Abirtega: Proprietary brand name for abiraterone 250 mg tablets
- CalRx
- MaxRP
Products and services
- Abirtega (abiraterone acetate) Generic abiraterone 250 mg tablets (120 per bottle, MaxRP $141), used for prostate cancer treatment. CivicaScript's first product, launched in August 2022.
- Capecitabine Generic capecitabine film-coated tablets for colorectal, breast, gastric, esophageal, gastroesophageal junction, or pancreatic cancer. Available in 150 mg (60 tablets, $38) and 500 mg (120 tablets, $84).
- Dalfampridine Generic dalfampridine 10 mg extended-release tablets (60 tablets, $37/month supply), a potassium channel blocker indicated to improve walking in adults with multiple sclerosis.
- Dimethyl fumarate Generic dimethyl fumarate delayed-release capsules for chronic inflammatory conditions. Available in 120 mg (14 capsules, $46) and 240 mg (60 capsules, $68).
- Droxidopa Generic droxidopa capsules for orthostatic hypotension. Available in 100 mg (90 capsules, $65), 200 mg (90 capsules, $109), and 300 mg (90 capsules, $153).
- Insulin glargine-yfgn Long-acting insulin glargine in prefilled pens (box of 5 pens, $55 MaxRP). Interchangeable with Lantus. Manufactured by Biocon Biologics. Available nationally; sold under CalRx brand in California.
- Ustekinumab-aauz Biosimilar ustekinumab (interchangeable with Stelara) for chronic inflammatory conditions. Human monoclonal antibody targeting IL-12 and IL-23 cytokines. Available in 45 mg ($625) and 90 mg ($1,035) prefilled syringes.
Quantifiable outcome
- Patients who switched to CivicaScript abiraterone saved about $81 per month on average (64 percent)
- +7 more outcomes
Companies that use CivicaScript
Customer profileNamed customers26 records
Segments3 records
Ideal customer profiles2 records
CivicaScript technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
CivicaScript partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and major.
- Biocon BiologicscoreBiocon Biologics manufactures insulin glargine-yfgn under its existing U.S. marketing approval. Partnership brings affordable biosimilar insulin to market.
- Fresenius KabicoreFresenius Kabi produces ustekinumab-aauz biosimilar. CivicaScript is the exclusive distributor of unbranded ustekinumab-aauz.
- California CalRx ProgramcorePartnership with California Department of Health Care Access and Information. Insulin glargine-yfgn carries the CalRx brand in California pharmacies.
- Breakthrough T1DmajorBreakthrough T1D (formerly JDRF) has joined with more than 25 other philanthropic partners and the states of California and Virginia to support Civica's development of three commonly prescribed insulin types.
- SelectHealth/ScripiusmajorNonprofit PBM (formerly SelectHealth) joined as a new partnering member in 2023.
- Navitus Health SolutionscoreNavitus Health Solutions is a PBM founding member. Brent Eberle joined CivicaScript in 2024 after two decades of leadership at Navitus.
- Affirmed RxcoreAffirmed Rx was the first pharmacy benefit manager to join as a partnering member in 2022.
- Elevance Health / CarelonRxcoreElevance Health (formerly Anthem) operates affiliated health plans covering more than 47 million people in the U.S. and joined as a founding member.
- CivicacoreCivicaScript was created by Civica (the parent nonprofit) and Blue Cross Blue Shield organizations. Civica provides operational infrastructure and manufacturing partnerships. Functional operations for CivicaScript are integrated with Civica.
- Blue Cross Blue Shield AssociationcoreBCBSA co-founded CivicaScript with Civica to bring affordable versions of commonly prescribed but high-priced generic medicines to market. The association continues to champion the model with Blue Plans nationwide.
- 18 Independent Blue Cross and Blue Shield Companiescore18 independent and locally operated Blue Cross and Blue Shield companies co-founded CivicaScript as founding members.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
CivicaScript competitors and assessment
Company assessmentEmerging players
- Phlow Corporation: Public-benefit pharmaceutical manufacturer focused on domestic production of essential medicines and APIs; similarly mission-driven with government/Civica-style backing, making it a natural peer in the nonprofit essential-medicines manufacturing space.
Broad incumbents
- Sandoz (Novartis division): World's largest generic and biosimilar manufacturer with thousands of SKUs across retail and specialty — comparable as a broad incumbent in low-cost generics, though pursuing a for-profit model with opposite incentives.
- Civica (Civica, Inc.): Parent nonprofit organization focused on hospital-administered generic drug shortages and price gouging; CivicaScript was created as Civica's outpatient/retail extension and shares operational infrastructure, manufacturing partnerships and the nonprofit mission.
- Teva Pharmaceutical Industries: World's largest generic manufacturer by volume with broad retail-generic presence; competes in essentially every category CivicaScript targets, though as a for-profit incumbent without pricing-transparency mechanisms.
- Hikma Pharmaceuticals: Specialty generics and injectables manufacturer with strong U.S. retail presence; comparable as a mid-size specialty-generic incumbent pursuing many of the same therapeutic indications (oncology, MS, etc.) as CivicaScript.
- Viatris: Global generics + biosimilars + specialty player with a deep specialty-generic portfolio (including authorized generics) overlapping CivicaScript's therapeutic categories and competing for the same payer formulary slots.
Direct peers
- Coherus BioSciences: Commercial biosimilar developer (ranibizumab, pegfilgrastim, adalimumab, ustekinumab) competing in the same therapeutic categories where CivicaScript is launching biosimilars, with similar cost-positioning strategy versus originator biologics.
- Mark Cuban Cost Plus Drug Company: Online pharmacy selling generics at cost-plus transparent markup with public price lists — the most direct peer in business model (transparent, mission-driven generic distribution) and target customer overlap (price-sensitive payers and uninsured patients).
- Alvotech: Pure-play biosimilar developer with interchangeable biosimilars (insulin, ustekinumab, denosumab, aflibercept) directly overlapping CivicaScript's biosimilar pipeline and interchangeable-insulin positioning with Biocon.
Others
- GoodRx: Public prescription price-transparency and discount platform; not a manufacturer but a peer in the consumer-facing drug-pricing-transparency thesis and partner/customer overlap with cost-sensitive patients and payers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CivicaScript social profiles
Digital presenceCivicaScript financial estimates
Financial estimateRevenue estimate
Valuation estimate
CivicaScript leadership team
Management profileNumber of profiles
Profiles10 records
CivicaScript funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CivicaScript M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CivicaScript
What does CivicaScript do?
CivicaScript is a nonprofit pharmaceutical company that manufactures and distributes low-cost essential generic medicines and biosimilars through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The company employs a Maximum Retail Price (MaxRP) pricing policy with QR-code-based verification to ensure price transparency throughout the supply chain, passing savings to patients and health plan members.
Is CivicaScript a public or private company?
CivicaScript is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CivicaScript founded?
CivicaScript was founded in 2020. It employs 1,001 to 5,000 people.
Where is CivicaScript based?
CivicaScript is headquartered in Lehi, United States, in the North America region.
How does CivicaScript make money?
Two revenue lines are on record. Generic Medicine Sales are the primary driver. The others are biosimilar Distribution.
Who are CivicaScript's main competitors?
Phlow Corporation is listed as an emerging player. Broad incumbents are Sandoz (Novartis division), Civica (Civica, Inc.), Teva Pharmaceutical Industries, Hikma Pharmaceuticals and Viatris. Direct peers are Coherus BioSciences, Mark Cuban Cost Plus Drug Company and Alvotech. GoodRx is listed as an others.
Does CivicaScript have an API?
No public API is recorded for CivicaScript.
What industry is CivicaScript in?
CivicaScript's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAFALAL, 340B Program Administration & Contract Pharmacy Services. Its NAICS code is 81341 and its SIC code is 2834.